Insider trades
Cameron Turtle, CEO of Spyre Therapeutics SYRE, has filed 0 purchases and 22 sales on the open market. Over the past 12 months that comes to a net sale of $5.9M. The latest trade was on 06/01.
Cameron Turtle
CEO
- Company
- Spyre Therapeutics SYRE
- First filing
- 23/11/27
- Trades
- 31 trades
- Buys / sales
- 0 / 22
- 12-month net buying
- −$5.9M
- Last trade
- 06/01
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
SYRE | Open-market sale10b5-1 plan | 06/01 | 06/03 | 15,000 sh3 trades | $70.43avg. | $1,056,486.02 | −2.4% |
SYRE | Open-market sale10b5-1 plan | 05/01 | 05/01 | 15,000 sh6 trades | $71.37avg. | $1,070,507 | −2.4% |
SYRE | Open-market sale10b5-1 plan | 04/01 | 04/03 | 15,000 sh2 trades | $49.33avg. | $739,912.32 | −2.3% |
SYRE | Open-market sale10b5-1 plan | 03/02 | 03/03 | 15,000 sh2 trades | $42.19avg. | $632,866 | −2.3% |
SYRE | Open-market sale10b5-1 plan | 02/02 | 02/04 | 15,000 sh2 trades | $32.80avg. | $492,045.15 | −2.2% |
SYRE | Open-market sale10b5-1 plan | 01/02 | 01/06 | 15,000 sh3 trades | $30.68avg. | $460,134.12 | −2.2% |
SYRE | Open-market sale10b5-1 plan | 25/12/01 | 25/12/03 | 15,000 sh2 trades | $29.02avg. | $435,355.5 | −2.1% |
SYRE | Open-market sale10b5-1 plan | 25/11/03 | 25/11/05 | 45,000 sh2 trades | $23.33avg. | $1,049,777.85 | −6.0% |